Have any questions? 706-721-6582 or cts@augusta.edu
- Enanta: EDP-938-103: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects of EDP-938 in Adult Hematopoietic Cell Transplant Recipients With Acute Respiratory Syncytial Virus Infection of the Upper Respiratory Tract
Clinical Trial
Enanta: EDP-938-103: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects of EDP-938 in Adult Hematopoietic Cell Transplant Recipients With Acute Respiratory Syncytial Virus Infection of the Upper Respiratory Tract
The purpose of this study is to evaluate the effect of the study drug, EDP-938, on the development of lower respiratory tract complications in subjects with an acute respiratory syncytial virus (RSV) infection, who have had a hematopoietic cell transplant. The study will also evaluate the safety and tolerability of EDP-938.
- Respiratory System
- EDP-938
- Hematopoietic Stem Cell Transplant (HCT)
- Respiratory Infection
- Respiratory Syncytial Virus (RSV)
Eligibility Criteria
- INCLUSION: 1. Age 18-75 years and have received a hematopoietic stem cell transplant 2. Confirmed respiratory syncytial virus (RSV) within 3 days prior to consent, with at least 1 protocol-defined respiratory symptom, and stable on room air EXCLUSION: 1. Hospitalized for primary lower respiratory tract disease of any cause, or co-infected with other respiratory viruses 2. Presence of any protocol-defined medical conditions that are not allowed in the study 3. Use of any medications/treatments prohibited by the study
RESEARCH. INNOVATION. DISCOVERY.